Codexis, Inc. disclosed new advances in RNA therapeutic manufacturing at TIDES USA 2026, including full-length small interfering RNA synthesis with stereochemical control using its ECO Synthesis Manufacturing Platform. The biotechnology company also revealed progress toward fully enzymatic RNA synthesis beginning from a single nucleotide, a development designed to eliminate reliance on chemically synthesized starter oligonucleotides as the RNA therapeutics industry confronts growing scalability, sustainability, and manufacturing efficiency pressures.

The announcement arrives at a critical point for the broader oligonucleotide sector. RNA therapeutics have already demonstrated clinical and commercial viability across several disease categories, but manufacturing complexity is increasingly emerging as one of the industry’s largest structural constraints. As developers pursue larger patient populations and more commercially ambitious indications, the economics and scalability of RNA production are becoming strategically important in ways that extend beyond traditional process optimization.

Why stereochemical control is becoming increasingly important for next-generation RNA therapeutics manufacturing scalability

One of the most significant aspects of Codexis, Inc.’s presentation involved its demonstration of full-length small interfering RNA synthesis with controlled phosphorothioate stereochemistry using an enzymatic manufacturing platform. Within RNA therapeutics manufacturing, phosphorothioate linkages are widely used to improve molecular stability and durability. However, controlling stereochemistry consistently across those linkages has historically been difficult, particularly at larger commercial manufacturing scale. Traditional chemical synthesis approaches often produce mixtures of stereoisomers that can complicate product uniformity and potentially influence therapeutic performance.

Industry observers increasingly believe stereochemical precision may become an important differentiator for next-generation RNA interference therapies. As the field matures, developers are focusing less exclusively on proof-of-concept efficacy and more heavily on manufacturing reproducibility, potency optimization, tolerability, and long-term dose efficiency.

That shift is especially relevant as small interfering RNA developers move beyond rare diseases toward broader chronic conditions requiring substantially larger production volumes. Conventional phosphoramidite chemistry workflows were developed during an era when many oligonucleotide therapies targeted relatively small patient populations. Scaling those manufacturing approaches economically for widespread commercial use remains challenging.

Codexis, Inc. appears to be positioning the ECO Synthesis Manufacturing Platform as a potential alternative architecture capable of improving both process precision and industrial scalability simultaneously. Drug developers participating in the company’s TIDES USA panel discussion suggested stereochemical control may eventually support higher active pharmaceutical ingredient concentrations and potentially enable alternative dosage approaches. If improved stereochemical precision enhances potency or reduces variability, manufacturers could theoretically lower material requirements per therapeutic dose over time.

However, the practical significance of stereochemical control remains an area regulators and commercial manufacturers will continue to evaluate cautiously. The RNA therapeutics sector still lacks extensive long-term commercial data proving that stereochemically controlled oligonucleotides consistently outperform highly optimized conventional products across broad therapeutic categories.

How enzymatic manufacturing platforms are challenging traditional oligonucleotide production economics

The broader importance of the ECO Synthesis Manufacturing Platform lies in its attempt to address several structural manufacturing limitations simultaneously. Conventional oligonucleotide synthesis relies heavily on solvent-intensive chemistry processes that become increasingly resource-intensive as production scales rise. Those workflows often involve extensive purification requirements, large solvent consumption, and complex waste management burdens. As RNA therapeutic pipelines expand commercially, pharmaceutical manufacturers are increasingly scrutinizing whether existing production models remain economically sustainable at much larger industrial scale.

Codexis, Inc.’s enzymatic manufacturing approach attempts to reposition RNA production around aqueous processing systems rather than heavily solvent-dependent chemistry. The biotechnology company reported more than a 50% reduction in global warming potential relative to conventional synthetic approaches, including approximately 2.7-fold lower global warming potential on an input materials basis. Sustainability metrics alone are unlikely to drive manufacturing transitions in pharmaceutical production, but environmental efficiency is becoming increasingly relevant as companies face mounting pressure around supply chain sustainability and operational resource consumption.

More importantly, aqueous enzymatic workflows could eventually simplify infrastructure requirements and reduce downstream purification complexity if industrial scalability claims are validated commercially. The RNA therapeutics sector is now entering a phase where manufacturing economics may become just as strategically important as clinical innovation. Earlier industry development cycles focused primarily on delivery technologies, target validation, and therapeutic efficacy. Those scientific questions remain important, but many developers are now confronting industrialization challenges that determine whether successful therapies can scale profitably for broader commercial deployment.

Still, pharmaceutical manufacturing transitions rarely occur quickly. Drug developers and contract manufacturing organizations remain highly conservative regarding process modifications, particularly when clinically validated chemistry workflows already exist. Regulatory familiarity with traditional oligonucleotide synthesis methods also creates operational inertia that newer enzymatic approaches must overcome gradually.

Why fully enzymatic fragment synthesis could become strategically important for future siRNA assembly methods

Another important aspect of Codexis, Inc.’s announcement involved its advancement toward initiating enzymatic RNA synthesis from a single nucleotide. That capability addresses an increasingly important issue within evolving small interfering RNA manufacturing strategies. Current enzymatic workflows often require chemically synthesized starter oligonucleotides to initiate nucleotide extension processes. Eliminating those chemically derived starting materials could simplify production architectures considerably.

The significance becomes larger in the context of fragment ligation strategies. As RNA molecules grow increasingly sophisticated, fragment-based assembly approaches are attracting greater industry interest because they may improve manufacturing flexibility and reduce inefficiencies associated with synthesizing longer oligonucleotide chains directly. Codexis, Inc. is positioning its engineered ligases alongside its enzymatic synthesis technologies as part of a broader integrated production framework for complex RNA therapeutics.

Industry scientists increasingly view ligation-driven manufacturing workflows as potentially important for future RNA therapeutic scalability. Fully enzymatic fragment production could theoretically reduce purification requirements, improve process efficiency, and create more modular manufacturing systems for increasingly advanced oligonucleotide architectures.

However, meaningful operational questions remain unresolved. The industry has not yet seen extensive commercial evidence demonstrating that enzymatic manufacturing systems can consistently outperform optimized conventional chemistry workflows across diverse therapeutic applications. Large-scale manufacturing reproducibility, impurity management, lot consistency, and operational reliability remain areas where pharmaceutical manufacturers will demand extensive validation data before committing to major infrastructure transitions.

Why the RNA therapeutics industry is increasingly prioritizing manufacturing innovation alongside clinical differentiation

The broader strategic importance of Codexis, Inc.’s positioning reflects a larger transition occurring throughout the RNA therapeutics industry. Once emerging therapeutic platforms achieve clinical credibility, manufacturing infrastructure frequently becomes one of the defining competitive battlegrounds. Similar patterns emerged previously across monoclonal antibodies, biologics manufacturing, and cell therapy production, where industrial scalability eventually became just as commercially important as scientific innovation itself.

RNA therapeutics appear to be entering that phase now. The sector is expanding beyond early niche indications into larger disease categories where manufacturing throughput, supply chain resilience, cost efficiency, and production consistency become materially more important.

As a result, enabling technologies capable of industrializing RNA production more efficiently may attract increasing strategic interest from pharmaceutical manufacturers, contract development organizations, and investors seeking infrastructure exposure within the broader RNA therapeutics ecosystem. Codexis, Inc. appears to be attempting to position itself less as a standalone therapeutic developer and more as a manufacturing technology enabler for the expanding oligonucleotide market. Infrastructure-focused biotechnology companies may benefit from broader sector growth regardless of which individual therapeutic platforms dominate clinically, but manufacturing technology adoption cycles are often slower and less predictable than early-stage platform enthusiasm initially suggests.

Clinicians, regulators, and manufacturing executives will now likely focus less on conceptual innovation and more on operational proof points. The next major questions surrounding the ECO Synthesis Manufacturing Platform will involve whether enzymatic stereochemical control can operate reproducibly at industrial scale while maintaining regulatory-grade product consistency and economically competitive manufacturing performance.

  Codexis, ECO Synthesis Manufacturing Platform, enzymatic RNA synthesis, Inc., oligonucleotide manufacturing, RNA interference, RNA therapeutics, siRNA, stereochemistry